The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
FDA grants CG-806 investigational new drug allowance for the treatment of AML
On June 29, 2020, the U.S. Food and Drug Administration (FDA) granted approval of an investigational new drug application for the initiation of a phase Ia/b study on CG-806 for the treatment of patients with acute myeloid leukemia.
CG-806 is an oral FLT3/BTK inhibitor. It demonstrates potent inhibition of wild type and FLT3 mutant forms as well as non-covalent inhibition of the wild type and Cys481Ser mutant forms of the BTK enzyme in murine leukemia models. CG-806 is under investigation in patients with B-cell malignancies, including chronic lymphocytic leukemia and non-Hodgkin lymphomas, who are resistant/refractory or intolerant to current therapies.
The FDA has allowed the initiation of a clinical trial in patients with relapsed/refractory acute myeloid leukemia at a starting dose of 450 mg, twice a day. The phase Ia/b study will start in the second half of 2020.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?